← Antihypertensives × blood pressure

Observational studyMedicine2016

Statins and risk for new-onset diabetes mellitus: A real-world cohort study using a clinical research database.

Dukyong Yoon et al.PubMed ↗Full text ↗Publisher ↗

  • Statin exposureno clear effectHigher NODM.Nothing cleared the noise.
  • Male genderlooks bad hereHigher NODM.Correlation only, not a test of it.
  • Baseline glucose per mg/dLlooks bad hereHigher NODM.Correlation only, not a test of it.
  • Hypertensionlooks bad hereHigher NODM.Correlation only, not a test of it.

What the trial testedas reported · 2016

Not counted

Probably raised NODM

1.9×1.4× to 2.4×

statin exposure vs matched nonexposed

Bigger than 8 in 10 on the map

As reported

HR 1.872, 95% CI 1.43–2.44

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Male gender went with higher NODM

1.9×1.5× to 2.5×

Male gender vs Female gender

Bigger than 8 in 10 on the map

As reported

HR 1.944, 95% CI 1.50–2.52

Correlation, not cause

Baseline glucose per mg/dL went with higher NODM

+1%+1% to +2%

baseline glucose per mg/dL vs per 1 mg/dL increase

Smaller than almost all for glycemic control

As reported

HR 1.014, 95% CI 1.01–1.02

Correlation, not cause

Hypertension went with higher NODM

2.2×1.5× to 3.3×

hypertension vs no hypertension

Bigger than 8 in 10 on the map

As reported

HR 2.232, 95% CI 1.51–3.29

+2 more in the walkthrough ↓

Who was studied, and how

900people in the Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in Acute Myocardial Infarction trial, from 2015
of them with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

statin exposure
matched nonexposed

Probably raised NODM1.9×

randomised

Already taking Male gender, or nottheir own situation, not assigned

on Male gender
Female gender

Male gender went with higher NODM1.9×

correlation, not a test

the abstract, start to end

… (HR) of NODM after statin exposure was 1.872 (95% confidence interval [CI], …

Male gender (HR, 1.944; 95% CI, 1.497-2.523), baseline glucose per mg/dL (HR, 1.014; 95% CI, 1.013-1.016), hypertension (HR, 2.232; 95% CI, 1.515-3.288), and thiazide use (HR, 1.337; 95% CI, 1.081-1.655) showed an increased risk for NODM, while angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker showed a decreased risk (HR, 0.774; 95% CI, 0.668-0.897).

← favours treatmentfavours comparator →
could be chance
NODMstatin exposure vs matched nonexposed
HR 1.8721.43–2.44
NODMMale gender vs Female gender
HR 1.9441.50–2.52
NODMbaseline glucose per mg/dL vs per 1 mg/dL increase
HR 1.0141.01–1.02
NODMhypertension vs no hypertension
HR 2.2321.51–3.29
NODMthiazide use vs no thiazide use
HR 1.3371.08–1.66
NODMangiotensin-converting enzyme inhibitor or angiotensin II receptor blocker vs no ACEI/ARB use
HR 0.7740.67–0.90
StatinsAntihypertensivesGlycemic controlBlood pressurePharmacokinetics & dosing
1 / 4

15 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it

The trial

NCT04945122phase 4900 enrolled2015
Full record →Abstract, authors, funding and every citing paper · PMID 27861386